Core Insights - BD (Becton, Dickinson and Company) has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to enhance research in deep human immune profiling and support the development of immune-mediated therapies [1][2] Group 1: Collaboration Details - The collaboration aims to develop and validate a high-parameter flow cytometry panel that captures key functional pathways in whole blood, including phosphorylation markers, to provide insights into single-cell responses to drugs or disease states [2] - A planned 1,000-patient immune profiling study will be conducted in partnership with the Penn Colton Center for Autoimmunity, expected to commence in the summer [2] - The project will utilize the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, and BD reagents, with BD teams managing reagents, instrumentation, and spectral data algorithms, while I3H teams will serve as scientific and clinical leads [2] Group 2: Technological Advancements - The BD FACSDiscover™ A8 Cell Analyzer is highlighted as the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, which will facilitate deeper insights into the human immune system [3] - The collaboration reflects a commitment to advancing science and health through the unlocking of the human immune system's potential [3] Group 3: Industry Impact - High-parameter single-cell studies are becoming increasingly central to understanding the human immune system, with BD's ecosystem of flow cytometers, single-cell systems, reagents, software, and informatics providing essential support for organizations like I3H [4] - The collaboration aims to translate immunological insights into quantitative, actionable information for discovery and clinical care teams globally [4]

Core Insights - BD (Becton, Dickinson and Company) has launched new configurations of the BD FACSDiscover™ A8 Cell Analyzers, enhancing accessibility to advanced spectral and real-time imaging technologies for various laboratories [1] - The new analyzers allow scientists to analyze over 50 characteristics of a single cell with high resolution and sensitivity, facilitating discoveries in immunology, cancer immunotherapy, and cell biology [1] - The introduction of three- and four-laser configurations complements the previously launched five-laser model, broadening the technology's reach to more labs globally [1] Product Features - BD SpectralFX™ Technology enables detailed analysis of single cells, while BD CellView™ Image Technology provides high-speed imaging for real-time spatial and morphological insights [1] - The analyzers feature high-throughput, walkaway automation, optimizing cost-per-insight economics through real-time imaging [1] - Intuitive software is designed for managing large datasets and standardization, enhancing user experience [1] Market Impact - The BD FACSDiscover™ A8 Cell Analyzer is rapidly being adopted by leading biopharmaceutical companies, with flexible financing options available for organizations facing capital expenditure constraints [1] - The technology is positioned to support a wide range of research needs, from basic to translational science, making it accessible to labs of all sizes [1] - BD continues to expand its ecosystem with new fluorochromes, such as BD Horizon RealViolet™ 828 and RealBlue™ 824, which enhance spectral flow cytometry capabilities [1]

Core Insights - BD reported strong financial results for Q3 of fiscal 2025, with revenues of $5.509 billion, reflecting a 10.4% increase compared to the previous year [4][9] - The company raised its full-year adjusted diluted EPS guidance to between $14.30 and $14.45, indicating a growth of 9.4% at the midpoint [9][16] - BD announced a strategic agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation, aiming to enhance its position in the life sciences and diagnostics market [2][10] Financial Performance - Revenues for Q3 2025 were $5.509 billion, up from $4.990 billion in Q3 2024, marking a 10.4% increase [4][9] - Adjusted diluted EPS rose to $3.68, a 5.1% increase from $3.50 in the prior year [4][9] - GAAP diluted EPS increased to $2.00, up 19.0% from $1.68 [4][9] Segment Performance - BD Medical segment revenues reached $2.927 billion, a 14.4% increase from $2.558 billion [8][38] - BD Life Sciences segment revenues were $1.254 billion, slightly down by 0.5% from $1.260 billion [11][38] - BD Interventional segment revenues increased by 7.2% to $1.328 billion from $1.240 billion [11][38] Geographic Performance - U.S. revenues were $3.181 billion, a 10.0% increase from $2.891 billion [6][38] - International revenues grew by 11.0% to $2.328 billion from $2.098 billion [6][38] Strategic Initiatives - The company plans to invest $35 million in a Nebraska facility to enhance production capabilities for its PosiFlush™ Prefilled Flush Syringe [10] - BD Life Sciences submitted an FDA application for the at-home BD Onclarity™ HPV Assay, which includes advanced self-collection technology [10] - The company achieved its Scope 1 and 2 greenhouse gas emissions reduction target for FY 2024, reflecting its commitment to sustainability [10]